Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy | Zendy

Andreas Schicho | Zendy; Philippe L. Pereira | Zendy; Michael Haimerl | Zendy; Christoph Nießen | Zendy; Katharina Michalik | Zendy; Lukas Philipp Beyer | Zendy; Christian Stroszczynski | Zendy; Philipp Wiggermann | Zendy

Open Access

Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy

Author(s) -

Andreas Schicho,

Philippe L. Pereira,

Michael Haimerl,

Christoph Nießen,

Katharina Michalik,

Lukas Philipp Beyer,

Christian Stroszczynski,

Philipp Wiggermann

Publication year - 2017

Publication title -

oncotarget

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.373

H-Index - 127

ISSN - 1949-2553

DOI - 10.18632/oncotarget.19997

Subject(s) - medicine , hepatocellular carcinoma , adverse effect , response evaluation criteria in solid tumors , single center , stage (stratigraphy) , gastroenterology , liver cancer , carcinoma , progressive disease , liver disease , oncology , surgery , disease , paleontology , biology

Hepatocellular carcinoma (HCC) is the 3rd leading cause of cancer-related death worldwide. The majority of HCCs are diagnosed in a stage that is not eligible for curative resection. For intermediate stage HCC, transarterial chemoembolization (TACE) is the recommended treatment. We evaluated the safety and efficacy of DSM (degradable starch microspheres) as embolic agent in transarterial chemoembolization (TACE) for the treatment of intermediate stage, non-resectable hepatocellular carcinoma (HCC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research